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Abstract
Antisense-mediated exon skipping has made significant progress as a therapeutic platform
in recent years, especially in the case of Duchenne muscular dystrophy (DMD). Despite
FDA approval of eteplirsen–the first-ever antisense drug clinically marketed for DMD–exon
skipping therapy still faces the significant hurdles of limited applicability and unknown trun-
cated protein function. In-frame exon skipping of dystrophin exons 45–55 represents a sig-
nificant approach to treating DMD, as a large proportion of patients harbor mutations within
this “hotspot” region. Additionally, patients harboring dystrophin exons 45–55 deletion muta-
tions are reported to have exceptionally mild to asymptomatic phenotypes. Here, we demon-
strate that a cocktail of phosphorodiamidate morpholino oligomers can effectively skip
dystrophin exons 45–55 in vitro in myotubes transdifferentiated from DMD patient fibroblast
cells. This is the first report of substantive exons 45–55 skipping in DMD patient cells. These
findings help validate the use of transdifferentiated patient fibroblast cells as a suitable cell
model for dystrophin exon skipping assays and further emphasize the feasibility of dystro-
phin exons 45–55 skipping in patients.
Introduction
Duchenne muscular dystrophy (DMD) is a lethal, progressive myopathy affecting approxi-
mately 1 in every 3600–5000 male births and is caused by deleterious mutations in the dystro-
phin (DMD) gene [1–4]. Mutations in DMD can also cause another milder form of muscular
dystrophy known as Becker muscular dystrophy (BMD) [5]. Typically, DMD arises from out-
of-frame mutations (~65% of patients) while BMD generally arises from in-frame mutations
(~82% of patients) [6–8].
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The observation that truncated dystrophin protein arising from in-frame mutant DMD
transcripts could still maintain partial functionality–as in the case of BMD–helped provide the
rationale for a therapeutic approach involving splice modulation via synthetic polymers. Anti-
sense oligonucleotides (AOs) are chemically modified nucleic acids which can hybridize to
pre-mRNA and can affect splicing and protein synthesis [9, 10]. By utilizing AOs, mutation-
carrying exons and flanking exons can be selectively removed or “skipped” from the final mes-
senger transcript, restoring the reading frame and producing a truncated protein which may
retain some functionality–in essence, exon skipping could convert a DMD phenotype to a
BMD phenotype [9, 11, 12]. Several in vitro and in vivo studies have now demonstrated the fea-
sibility of antisense-mediated exon skipping in DMD [13–18] and the first-ever clinical AO
drug for treating DMD, eteplirsen (Exondys 51), was approved by the FDA in 2016 [19].
Exon skipping as a therapy for treating DMD is not without its challenges. The first major
drawback is the requirement for specifically-targeted AO sequences for any given exon. This
means a great deal of time and money needs to be spent in evaluating individual AO sequences
to address a wide range of patient mutation patterns. Another big challenge is determining the
stability and functionality of the truncated proteins [20, 21]. A solution to the specific issue of
validating oligo sequences for accommodating multiple mutation patterns is using analytical
software algorithms to predict AO exon skipping efficiency, as has been described [22]. In con-
junction with in silico predictive tools, another possible avenue to circumventing these issues is
multi-exon skipping of DMD exons 45–55. First, in terms of applicability, a large proportion
of all DMD patients (~47%) harbor mutations within this “hot-spot” region of exons 45–55,
and up to ~63% of DMD patients with deletion mutations could benefit from skipping exons
45–55 [23, 24]. Multi-exon skipping of exons 45–55 would also address the issue of unknown
truncated protein stability/function, as patients exhibiting this particular pattern of deletion
mutation present with exceptionally mild symptoms or are asymptomatic [23–25].
As more AOs are required to bind to the same transcript to ensure maintenance of the
open reading frame, dosage levels must be sufficiently high enough to facilitate skipping multi-
ple exons while avoiding overt toxicity. While several AO chemistries have been designed and
tested [9, 26], one of the most promising antisense chemistries developed is the phosphorodia-
midate morpholino oligomer (morpholino or PMO). The stability, safety, and tolerability of
PMOs have been well-documented [27–29], even at high doses [30, 31], and it is worth noting
that the clinically-utilized eteplirsen is a PMO chemistry [32]. PMOs could therefore address
issues regarding the potential toxicity of AO cocktails as they could be delivered at concentra-
tions high enough to facilitate exons 45–55 skipping while avoiding toxic effects. Our group
has demonstrated this previously in a dog model of DMD, using a cocktail of PMOs to effec-
tively skip multiple exons in vivo without overt toxicity [14].
The first step toward clinical utility of any AO drug is the demonstration of its efficacy in
vitro; thus, the establishment of a suitable in vitro exon skipping assay for determining dystro-
phin exon skipping is essential. To this end, muscle cell types (myoblasts and myotubes)
expressing dystrophin are typically used. However, the collection of patient muscle tissue via
biopsy is highly invasive, requires specialized equipment and preservation techniques [33],
and yields only a small amount of what are often poorly proliferative cells [34]. Myotubes con-
verted from fibroblasts via MYOD1 transduction express dystrophin at levels sufficient to
determine the effectiveness of AOs at facilitating DMD exon skipping and protein rescue [13]
and represent an alternative approach to biopsied patient muscle tissue at evaluating exon
skipping efficiency in vitro.
In this study, we tested the exons 45–55 skipping efficacy of PMO sequences designed using
a predictive software tool by transfecting PMO cocktails into transdifferentiated DMD patient
myotubes harboring deletion mutations amenable to reading frame correction via exons 45–
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55 skipping. We observed a dose-dependent production of exons 45–55 skipped transcripts as
well as the rescue of dystrophin protein in DMD patient cells. This is the first-ever demonstra-
tion of robust dystrophin exons 45–55 skipping in transdifferentiated patient cells.
Materials and methods
Cell culture
Human DMD patient fibroblast cells harboring out-of-frame deletion mutations of dystrophin
exons 45–50 (ID: GM05017) and exons 46–50 (ID: GM05162), as well as healthy human
fibroblasts (ID: GM23815) were originally obtained in 2012 from the Coriell Institute for Med-
ical Research (Camden, NJ, USA). DMD fibroblasts and human embryonic kidney cells
(HEK293T; Cedarlane, ON, Canada) were cultured in DMEM/F-12 growth media (Invitro-
gen) containing 10% fetal bovine serum (FBS) and 0.5% penicillin/streptomycin and stored in
a CO2 incubator at 37˚C. For myotube differentiation, FACS-sorted fibroblasts were cultured
in DMEM/F-12 (Invitrogen) containing 2% horse serum, 1X ITS Liquid Media Supplement
(Sigma-Aldrich), and 0.5% penicillin/streptomycin.
MYOD1 transduction and cell sorting
A pRetroX-IRES-ZsGreen1 expression vector (Clontech) containing the human MYOD1 cod-
ing sequence, a pVSV-G envelope vector, and a gap-pol expression vector were prepared as
described previously [13]. These vectors were co-transfected into HEK 293T cells via standard
calcium phosphate transfection. Viral supernatant was collected after 48–72 h incubation and
added to 70–80% confluent DMD fibroblast cells (40 mL viral supernatant in a T225 flask)
along with 8 μg/ml polybrene (Sigma-Aldrich). DMD fibroblasts were incubated for 24 h at
37˚C, then the viral supernatant was replaced with fresh growth media and cells were incu-
bated for an additional 48 h. Cell sorting via FACS was performed on a FACS Area III flow
cytometry system (BD Bioscience) by the Faculty of Medicine and Dentistry’s Flow Cytometry
Core at the University of Alberta. Sorted ZsGreen-positive cells were seeded at 1x105 cells in
500 μl of total volume into each well of a 12-well collagen-coated plate and incubated in growth
media for 24 h. Culture media was then changed to differentiation media and cells were incu-
bated until myotubes formed, with differentiation media being replaced every 2–3 d.
Design and transfection of PMOs
The in silico design of 30-mer AOs targeting DMD exons 45–55 was performed using a predic-
tive software algorithm developed by our group [22] and PMOs were synthesized by Gene
Tools (Oregon, USA). PMOs at 1, 3 or 10 μM each were transfected as a cocktail into differen-
tiated DMD myotubes using 6 μM Endo-Porter transfection reagent (Gene Tools). Cells were
incubated with PMO for 48 h and then media was changed to fresh media and cells were incu-
bated an additional 72 h before harvesting for analysis.
RT-PCR analysis and sequencing
Total RNA was collected from cells using Trizol (Invitrogen) and 200 ng of total RNA was
used for analyzing exons 45–55 skipping efficiency via SuperScript III One-Step RT-PCR
System with Platinum Taq DNA Polymerase (Invitrogen). Primers for dystrophin: FWD
GACAAGGGCGATTTGACAG; REV TCCGAAGTTCACTCCACTTG. Primers for GAPDH: FWD
TCCCTGAGCTGAACGGGAAG; REV GGAGGAGTGGGTGTCGCTGT.PCR products were elec-
trophoresed on a 1.5% agarose gel and bands were excised using a Wizard1 SV Gel and PCR
Exons 45-55 skipping in dystrophin
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Clean-Up kit (Promega). Sanger sequencing of excised bands was performed by The Applied
Genomics Core at the University of Alberta.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde (PFA) for 5 min at room temperature, then permea-
bilized and blocked with 0.5% Triton X-100 and 10% goat serum for 20 minutes at room tem-
perature. Cells were incubated in primary antibody for 1 h at room temperature at a 1:30 ratio
for anti-desmin (ab8592, Abcam), anti-dystrophin (NCL-DYS1, Novocastra), and anti-myosin
heavy chain (NCL-MHCf, Novocastra). Cells were incubated with 1:500 anti-rabbit or mouse
IgG (H+L) highly cross-adsorbed secondary antibody, Alexa Fluor 594 (Invitrogen). SlowFade
Gold Antifade Mountant with DAPI (Invitrogen) was added and cells were stored at 4˚C.
Results
Patient mutation analysis and exon skipping approach
DMD fibroblast cell lines GM05162 and GM05017 supplied by the Coriell Institute were
originally sampled from two clinically affected males aged 13 and 12, respectively. Both individ-
uals exhibited progressive muscle weakness and were wheelchair bound before or at age 10.
GM05162 harbors a deletion of dystrophin exons 46–50, resulting in an out-of-frame product
which requires a cocktail of 6 PMOs and skipping of exons 45, 51–55 to restore the reading
frame (Fig 1A). GM05017 contains an out-of-frame deletion of exons 45–50, requiring a cock-
tail of 5 PMOs and skipping of exons 51–55 (Fig 1B). Based on these mutation patterns, we uti-
lized our exon skipping predictive tool [22] to calculate the expected exon skipping efficiencies
for PMO sequences of 30-mer length covering all possible target sites for the corresponding
exons. PMO sequences used are described in Table 1. For our oligo design, we also considered
the binding free energy values between AOs and selected oligos with>-9 ΔG (Table 2). The in-
frame skipping of dystrophin exons 45–55 produces a truncated product containing a hybrid
rod repeat that is known to retain similar function to the full-length protein (Fig 1C).
MYOD1 transduction of DMD fibroblasts and conversion to myotubes
An expression vector containing ZsGreen and the human MYOD1 coding sequence was deliv-
ered via retrovirus into human DMD patient fibroblast cells and healthy human fibroblasts (Fig
2A) [13, 35]. Following transduction, ZsGreen-positive cells were sorted via flow cytometry
(Fig 2B) and seeded into collagen-coated 12-well plates. After adherence, cells were cultured in
reduced-serum media to induce myogenic differentiation. Morphological examination showed
that ZsGreen-positive MYOD1-transduced cells had become elongated and contained multiple
nuclei (Fig 2C)–hallmarks of myotube morphology. To confirm successful transdifferentiation
of fibroblasts to muscle cell type, we performed immunostaining for several markers of muscle
identity. These cells expressed muscle-specific proteins myosin heavy chain and desmin, and
healthy cells expressed dystrophin (Fig 2D). We then utilized a time-course expression assay to
compare dystrophin mRNA expression between transdifferentiated healthy and patient cells. In
both healthy and DMD patient cells, dystrophin mRNA expression was detectable by RT-PCR
as early as 3 d after addition of differentiation media (Fig 2E).
Antisense-mediated multi-exon skipping of dystrophin exons 45–55 in
DMD patient cell lines using PMO cocktails
Based on respective mutation patterns, skipping of dystrophin exons 45–55 in cell line
GM05162 requires a cocktail of 6 PMOs, while skipping of exons 45–55 in cell line GM05017
Exons 45-55 skipping in dystrophin
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requires a cocktail of 5 PMOs (Fig 1A and 1B). Following transfection of PMO cocktails,
RT-PCR analysis showed exon skipped products of the expected molecular weight in both cell
lines in a dose-dependent manner (Fig 3A). Sanger sequencing of exon-skipped products
revealed that the skipped products contained in-frame concatenations of DMD exons 44 and
56 (Fig 3A). Immunostaining showed some rescue of dystrophin protein in both PMO-treated
cell lines (Fig 3B).
Discussion
In this study, we demonstrated the feasibility of skipping dystrophin exons 45–55 in vitro using
human DMD patients’ myotubes converted from fibroblasts. This is the first successful dem-
onstration of robust, dose-dependent dystrophin exons 45–55 skipping in DMD patient cells.
While earlier attempts at exons 45–55 skipping in patient cells were unsuccessful [36], our
results emphasize the importance of AO sequence optimization and highlight the utility of in
silico predictive screening for potential AO sequences.
Fig 1. Mutation analysis and exon skipping approach. (A) Cell line GM05162 harbors an out-of-frame deletion mutation of dystrophin exons 46–50, which requires
skipping 6 exons via PMOs to correct the reading frame. Sides of schematic boxes represent the codon phase. (B) Cell line GM05017 harbors an out-of-frame deletion
mutation of dystrophin exons 45–50, which requires skipping 5 exons via PMOs to correct the reading frame. (C) Structure of full-length dystrophin and exons 45-
55-deleted dystrophin. The truncated dystrophin generated by exons 45–55 skipping contains a hybrid rod repeat (yellow bars) of rods 17 and 22. Actin bind, actin-
binding domain; H1-4, hinge domain 1–4; CRD, cysteine-rich domain; CTD, C-terminal domain.
https://doi.org/10.1371/journal.pone.0197084.g001
Table 1. PMO sequences used for exons 45–55 skipping.
Exon Target Distance from acceptor splice site Sequence (5’ to 3’) Predicted Skipping (%)
Ex45 Ac9 GACAACAGTTTGCCGCTGCCCAATGCCATC 76.2
Ex51 Ac5 AGGTTGTGTCACCAGAGTAACAGTCTGAGT 73.0
Ex52 Ac24 GGTAATGAGTTCTTCCAACTGGGGACGCCT 90.1
Ex53 Ac9 GTTCTTGTACTTCATCCCACTGATTCTGAA 73.9
Ex54 Ac42 GAGAAGTTTCAGGGCCAAGTCATTTGCCAC 62.0
Ex55 Ac0 TCTTCCAAAGCAGCCTCTCGCTCACTCACC 120.4
https://doi.org/10.1371/journal.pone.0197084.t001
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This is also the first demonstration of exons 45–55 skipping in transdifferentiated cells,
which underscores the suitability of using patient fibroblast cells as an alternative to cells
obtained via muscle biopsy for evaluating exon skipping. This method of measuring exon skip-
ping efficiency in transdifferentiated myotubes offers advantages to other assays, such as easy
monitoring of MYOD1 transduction efficiency via ZsGreen signal and effective induction of
dystrophin expression, which can be difficult to induce [37].
Table 2. Binding free energies between PMOs used for exons 45–55 skipping.
Binding Free Energy (ΔG) between PMOs
Exon Target 45 51 52 53 54 55
45 -4.5 -6.7 -6.7 -2.9 -3.3 -6.2
51 -8.7 -5.4 -6.5 -5.9 -7.9
52 -4.2 -3.2 -7.2 -5.3




Fig 2. Transdifferentiation of DMD fibroblasts to myotubes. (A) Schematic diagram of MYOD1 expression vector. (B) Histogram comparison of ZsGreen
fluorescence signal vs cell number between healthy and DMD patient fibroblast cells transduced with MYOD1 expression vector. Representative images shown, although
results between either patient cell line were similar. (C) Immunocytochemistry of transduced fibroblasts following 18 d (MYOD1), 15 d (MyHC, myosin heavy chain),
18 d (desmin), and 24 d (dystrophin) differentiation, respectively. Pictured are results from a healthy cell line. Nuclei counterstained with DAPI. Scale bars: 100 μm. (D)
RT-PCR time-course analysis of dystrophin expression in healthy and patient DMD transdifferentiated fibroblasts. Images are representative, with dystrophin
expression observed in all transdifferentiated cell lines.
https://doi.org/10.1371/journal.pone.0197084.g002
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Our group previously reported the efficacy of antisense-mediated dystrophin exons 45–55
skipping and rescue of dystrophin protein in vivo using a cocktail of vivo-morpholinos
(vPMOs) in a mouse model of DMD [14, 15]. Before such new-generation antisense oligos can
be effective and safe in vivo they require rigorous sequence optimization in vitro. Here, we
emphasize an effective method for in vitro assessment of exon skipping efficacy in transdiffer-
entiated human DMD patient cells which can pave the way for subsequent in vivo and clinical
studies. By utilizing muscle cells obtained through fibroblast transdifferentiation, researchers
can access an effective cell model for assessing the exon skipping ability of novel antisense
chemistries and gene sequence targets while avoiding challenges associated with utilizing mus-
cle harvested from patient biopsies, such as the limited availability and poor proliferative abil-
ity of patient muscle samples [34, 38].
Currently, the only clinically available exon skipping therapy is Sarepta’s exon 51 skipping
drug, eteplirsen (Exondys 51). Notwithstanding FDA approval of the drug in 2016 [19],
eteplirsen has remained surrounded by controversy, with concerns being raised as to its clini-
cal efficacy [39]. Furthermore, exon 51 skipping is limited in its therapeutic applicability, with
an estimated ~13% of all DMD patients being able to benefit from such an approach [40].
Several antisense-mediated exon skipping approaches are currently being evaluated across
various clinical trials, targeting DMD exons 44 (NCT02958202), 45 (NCT02667483), 51
(NCT03375255), and 53 (NCT03167255); the respective therapeutic applicability of these tar-
gets is ~6%, ~8%, ~13%, and ~8% [40]. Notably, while the combined applicability of the
Fig 3. Multi-exon skipping of dystrophin exons 45–55 in transdifferentiated DMD patient cells. (A) RT-PCR for dystrophin following cocktail PMO transfection in
transdifferentiated DMD patient cells. Cells were treated with 1, 3, or 10 μM each PMO. Expected molecular weight of dystrophin exons 45–55 skipped mRNA is 308 bp.
(B) Representative immunocytochemistry of transduced DMD fibroblasts following PMO cocktail transfection. Nuclei counterstained with DAPI. Scale bars: 100 μm.
https://doi.org/10.1371/journal.pone.0197084.g003
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aforementioned exon skipping approaches is ~35%, a single exon skipping approach targeting
exons 45–55 would theoretically be amenable to ~47% of all DMD patients [24]. In addition to
increased patient applicability, another advantage of skipping DMD exons 45–55 is that the
resulting truncated protein is remarkably stable, as evidenced by patients harboring exons 45–
55 deletion mutations who are either asymptomatic or display exceptionally mild symptoms
[24].
In conclusion, our findings support the feasibility of future translation of the dystrophin
exons 45–55 skipping approach into clinical practice for treating DMD. Potential hurdles such
as possible side-effects of intermediate transcripts, toxicity assessment, and optimized PMO
cocktail delivery will need to be addressed in future investigations. The development of a drug
cocktail approach may also necessitate modification of existing regulatory body guidelines
which currently consider individual AO sequences to be separate drugs. According to existing
regulations, each individual component of a cocktail drug approach, including all possible
combinations within that cocktail, would be required to undergo rigorous toxicological testing
[41]. This creates significant barriers to the development of a drug cocktail approach which are
both expensive and time-consuming to surmount.
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